News and Events

Mar 25, 2024

NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13

Nov 14, 2023

NIMML Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)

Nov 02, 2023

NIMML Announces Publication on the Safety, Efficacy and Novel LANCL2 Mechanism of Action of Omilancor in Inflammatory Bowel Diseases

Oct 23, 2023

NIMML Announces Positive Results of Omilancor Clinical Trials in Ulcerative Colitis and Crohn’s Disease at the American College of Gastroenterology 2023 Annual Scientific Meeting

Sep 12, 2023

NIMML Announces Publication of New Mechanistic Insights on the Metabolic Control of Inflammation and Infection in Scientific Reports

< Previous